Retrieve available abstracts of 30 articles: HTML format
Single Articles
September 2025
CENTOR RM, Zimetbaum P Annals On Call - Atrial Fibrillation: When Ablation Is the Way to Go.
Ann Intern Med. 2025 Sep 2:e2503841OC. doi: 10.7326/ANNALS-25-03841. PubMed
August 2025
WEITZ HH, Merli GJ, Lip G Web Exclusive. Annals Consult Guys - Anticoagulation, Atrial Fibrillation, and
Lower Gastrointestinal Bleeding.
Ann Intern Med. 2025;178:e2503595CG. PubMed
July 2025
Annals Video Summary - Catheter and Surgical Ablation for Atrial Fibrillation: A
Systematic Review and Meta-analysis.
Ann Intern Med. 2025 Jul 1:e2502118VS. doi: 10.7326/ANNALS-25-02118. PubMed
WAKS JW, Zimetbaum P The Significant Benefits of Ablation for Rhythm Control of Atrial Fibrillation.
Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02222. PubMed
MONTANE B, Zhang S, Wolfe JD, Prime S, et al Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and
Meta-analysis.
Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-00253. PubMedAbstract available
June 2025
KATSANOS AH, Douketis JD In survivors of ICH with AF, DOACs reduced incident ischemic stroke and increased
recurrent ICH at a median 1.4 y.
Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-01772. PubMedAbstract available
OGUNTALA JO, Yan AT In AF with stable CAD, an OAC alone does not increase ischemic events and reduces
major bleeding vs. OAC + SAPT at a mean 22 mo.
Ann Intern Med. 2025;178:JC65. PubMedAbstract available
May 2025
ALBERTS MJ In patients with subclinical AF, apixaban vs. aspirin reduced stroke or systemic
embolism at 3.5 y in those with previous stroke or TIA.
Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-25-01330. PubMedAbstract available
MANSOOR H, Elgendy IY In AF with recent ACS or PCI, apixaban reduced total bleeding vs. VKA; aspirin
increased total bleeding vs. placebo at 6 mo.
Ann Intern Med. 2025;178:JC57. PubMedAbstract available
KHATTAK S, Al-Ansari A, Alfaraidhy M, Rajah F, et al Cardiology: What You May Have Missed in 2024.
Ann Intern Med. 2025;178. PubMedAbstract available
April 2025
ABDEL-QADIR H, Gunn M, Fang J, Odugbemi T, et al Risk for Stroke After Newly Diagnosed Atrial Fibrillation During Hospitalization
for Other Primary Diagnoses : A Retrospective Cohort Study.
Ann Intern Med. 2025 Apr 22. doi: 10.7326/ANNALS-24-01967. PubMedAbstract available
PATEL NS, Joglar JA A New Perspective on Atrial Fibrillation "Provoked" by Hospitalization.
Ann Intern Med. 2025 Apr 22. doi: 10.7326/ANNALS-25-01073. PubMed
March 2025
LADER EW In previous MI with ventricular tachycardia (VT), catheter ablation reduced
mortality or VT events more than antiarrhythmic drug therapy at 4 y.
Ann Intern Med. 2025 Mar 4. doi: 10.7326/ANNALS-25-00336. PubMedAbstract available
February 2025
SMETANA GW, Gelfand EV, Tung P, Burns RB, et al How Would You Manage This Patient With Recent-Onset Atrial Fibrillation? Grand
Rounds Discussion From Beth Israel Deaconess Medical Center.
Ann Intern Med. 2025 Feb 11. doi: 10.7326/ANNALS-24-03490. PubMedAbstract available
SHARMA M, Srivastava A In acute ischemic stroke with AF, early DOAC initiation was noninferior to
delayed initiation for ischemic and hemorrhagic outcomes at 90 d.
Ann Intern Med. 2025 Feb 4. doi: 10.7326/ANNALS-24-03879. PubMedAbstract available
January 2025
BATES ER In subclinical AF, apixaban vs. aspirin reduced stroke or systemic embolism at
3.5 y, regardless of duration of recent subclinical AF episodes.
Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-03370. PubMedAbstract available
November 2024
ROMITI GF, Talerico G In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic
embolism trended higher with CHA(2)DS(2)-VASc >4.
Ann Intern Med. 2024;177:JC125. PubMedAbstract available
July 2024
SIMON TG, Singer DE, Zhang Y, Mastrorilli JM, et al Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in
Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
Ann Intern Med. 2024 Jul 9. doi: 10.7326/M23-3067. PubMedAbstract available
BARNES GD In device-detected AF, DOACs vs. aspirin or placebo reduce ischemic stroke and
increase major bleeding.
Ann Intern Med. 2024 Jul 2. doi: 10.7326/ANNALS-24-00652. PubMedAbstract available
June 2024
WEITZ HH, Merli GJ, Lip GYH Annals Consult Guys - The ABCs of Atrial Fibrillation.
Ann Intern Med. 2024;177:e2400618CG. PubMed
FIELD TS In cryptogenic stroke and atrial cardiopathy, apixaban did not reduce recurrent
stroke vs. aspirin.
Ann Intern Med. 2024;177:JC65. PubMedAbstract available
May 2024
SPOSATO LA, Hill MD In AF, CHA(2)DS(2)-VASc 1 subgroups did not differ for predicting risk for
arterial thromboembolism at 1 y.
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0023. PubMedAbstract available
DUNN A In older patients with AF and frailty, switching from VKA to NOAC therapy
increased a composite of major or CRNM bleeding at 12 mo.
Ann Intern Med. 2024;177:JC57. PubMedAbstract available
March 2024
SHADRIN IY, Newby LK In subclinical AF, apixaban reduced stroke or systemic embolism but increased
major bleeding vs. aspirin at 3.5 y.
Ann Intern Med. 2024;177:JC26. PubMedAbstract available
January 2024
ISHIGUCHI H, Lip GYH In symptomatic AF, catheter ablation vs. medical therapy reduced depression and
anxiety symptoms at 12 mo.
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0105. PubMedAbstract available
LOPEZ J, Borzak S In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or
myocardial injury after noncardiac surgery at 14 d.
Ann Intern Med. 2024;177:JC3. PubMedAbstract available
December 2023
BROPHY J In symptomatic AF with end-stage HF, adding catheter ablation to medical therapy
improved clinical outcomes at 18 mo.
Ann Intern Med. 2023;176:JC137. PubMedAbstract available
October 2023
MCINTYRE WF, Vadakken ME, Connolly SJ, Mendoza PA, et al Atrial Fibrillation Recurrence in Patients With Transient New-Onset Atrial
Fibrillation Detected During Hospitalization for Noncardiac Surgery or Medical
Illness : A Matched Cohort Study.
Ann Intern Med. 2023 Oct 3. doi: 10.7326/M23-1411. PubMedAbstract available
BARNES GD In adults, MRAs reduce AF occurrence vs. non-MRAs.
Ann Intern Med. 2023;176:JC114. PubMedAbstract available
September 2023
TON IT, Moon J, Sengul A, Mody FV, et al Evidence-Based Cardiovascular Disease Medicines' Availability in Low-Cost Generic
Drug Programs in the United States : A Cross-Sectional Study.
Ann Intern Med. 2023 Sep 5. doi: 10.7326/M23-0287. PubMedAbstract available